Dailypharm Live Search Close

Dupixent can be used by all age groups

By | translator Choi HeeYoung

21.12.14 12:04:15

°¡³ª´Ù¶ó 0
Share 52 weeks of long-term data and youth administration experience in Korea

onfirmation of validity and safety profile consistent with clinical practice

Point out rigid benefit standards, the subjective indicators should be reflected


Dupixent, atopic dermatitis (Eczema) treatment that marks its third anniversary, is becoming the only biological agent available for all ages. Doctors agreed, "It is time to show flexibility in applying Dupixent benefits that have secured long-term effectiveness and safety."

At an online seminar held by Sanofi to mark the 3rd anniversary of its launch in Korea on the 13th, Ahn Ji-young, a dermatologist at the National Medical Center, and Na Chan-ho, a dermatologist at Chosun University Hospital, shared their long-term Dupixent administration experience in 52 weeks (1 year) in domestic adult atopic dermatitis patients.

Professor Ahn's 52-week long-term data is a study that analyzed the me

(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)